PAVmed

PAVmed Net Debt

The Net Debt of PAVmed (PAVM) as of Nov 4, 2026 is 11.81 M USD. In the previous year, Net Debt was 30.68 M USD — a change of -61.50% (lower).

Net Debt

11.81 MUSD

YoY

-61.50%

Last updated:

Net Debt of PAVmed is 2025 11.81 M USD. Net Debt of PAVmed was 2024 30.68 M USD. It decreases by -61.50% lower compared to the previous year.

The PAVmed Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
2.35 M USD
Jan 1, 2018
-319,119.00 USD
Jan 1, 2019
1.92 M USD
Jan 1, 2020
-2.56 M USD
Jan 1, 2022
-6.11 M USD
Jan 1, 2023
29.09 M USD
Jan 1, 2024
30.68 M USD
Jan 1, 2025
11.81 M USD
The PAVmed Net Debt history
YEARNet DebtYoY
11.81 MUSD-61.50%
30.68 MUSD+5.46%
29.09 MUSD-575.88%
-6.11 MUSD+138.94%
-2.56 MUSD-233.25%
1.92 MUSD-701.58%
-319,119.00USD-113.56%
2.35 MUSD-501.84%
-585,680.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PAVmed Stock analysis

What does PAVmed do? PAVmed, Inc. generates revenue through the development and commercialization of medical devices including PortIO, a vascular access device without central venous system access or indwelling intravascular components, and CarpX, a percutaneous device for carpal tunnel syndrome treatment. The company also offers NextCath, a self-anchoring catheter eliminating the need for suturing or traditional anchoring methods, and DisappEAR, antibiotic-eluting resorbable ear tubes utilizing aqueous silk technology. Additional products include NextFlo, a disposable infusion system with variable flow resistors, and Caldus, a disposable tissue ablation device. Medical device companies and healthcare providers purchase these products for patient treatment and surgical procedures. The firm's product portfolio targets specific medical needs such as vascular access, orthopedic procedures, and ear treatments. PortIO serves patients requiring long-term vascular access without traditional central line risks. CarpX addresses carpal tunnel syndrome through minimally invasive procedures. DisappEAR provides a solution for ear tube insertion using resorbable technology, reducing the need for follow-up surgeries. NextCath streamlines catheter placement in medical settings. PAVmed's commercial strategy focuses on medical device companies and healthcare providers seeking innovative solutions for vascular access, orthopedic interventions, and ear care. The company's products are designed to improve patient outcomes while reducing procedural complexity and costs. By leveraging proprietary technologies like aqueous silk for DisappEAR, PAVmed differentiates its offerings in the medical device market. PAVmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PAVmed stock

Net Debt of PAVmed is 11.81 M USD in 2025.

Net Debt of PAVmed changed from 30.68 M USD to 11.81 M USD, representing a -61.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt PAVmed since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's PAVmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PAVmed

All Key Metrics — PAVmed